A5101765530- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- Cancer therapeutics and mechanisms
- Neuroendocrine Tumor Research Advances
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Angiogenesis and VEGF in Cancer
- Oral microbiology and periodontitis research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Optical Coherence Tomography Applications
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Advanced Fluorescence Microscopy Techniques
- Medical Imaging Techniques and Applications
- Cancer-related Molecular Pathways
- Cancer Genomics and Diagnostics
- Salivary Gland Disorders and Functions
- Radiomics and Machine Learning in Medical Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Immunotherapy and Immune Responses
- Adenosine and Purinergic Signaling
Kurume University
2014-2025
Koga Hospital
2018-2024
National Center for Global Health and Medicine
2022-2024
Juntendo University
2024
Ehime University Hospital
2023
Odawara Municipal Hospital
2020
Eisai (Japan)
1990-2019
Fukuoka Dental College
1998-2019
Massachusetts General Hospital
2000-2018
Kurume University Hospital
2016-2018
Lenvatinib is a multiple receptor tyrosine kinase inhibitor targeting mainly vascular endothelial growth factor (VEGF) and fibroblast (FGF) receptors. We investigated the immunomodulatory activities of lenvatinib in tumor microenvironment its mechanisms enhanced antitumor activity when combined with programmed cell death-1 (PD-1) blockade. Antitumor was examined immunodeficient immunocompetent mouse models. Single-cell analysis, flow cytometric immunohistochemistry were used to analyze...
Abstract Angiogenesis inhibitors such as lenvatinib and sorafenib, an immune checkpoint inhibitor ( ICI ), nivolumab, are used for anticancer therapies against advanced hepatocellular carcinoma HCC ). Combination treatments comprising angiogenesis plus s promising options improving clinical benefits in patients, trials ongoing. Here, we investigated the antitumor immunomodulatory activities of (a multiple receptor tyrosine kinase targeting vascular endothelial growth factor 1‐3, fibroblast...
Abstract Purpose: E7080, an oral multitargeted receptor tyrosine kinase inhibitor, has antiangiogenic and antitumor activity. This Phase I study investigated maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK), pharmacodynamics (PD), efficacy in patients with advanced solid tumors. Experimental Design: In this sequential, dose-escalation, open-label E7080 was administered orally twice daily a 2-week-on/1-week-off cycle. Plasma angiogenic proteins, circulating...
Ramucirumab plus docetaxel prolongs survival in patients with non-small cell lung cancer (NSCLC) disease progression after platinum-based therapy. This phase II, double-blind, randomized, placebo-controlled study assessed efficacy and safety of second-line ramucirumab-docetaxel Japanese NSCLC.Patients NSCLC therapy (28 sites; 19 December, 2012 to 22 May, 2015) were randomized (computer-generated sequence) ramucirumab 10mg/kg or placebo, followed by 60mg/m(2) (Day 1, 21-day cycle). Prior...
Abstract The most common event responsible for resistance to first- and second-generation (1st 2nd) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is acquisition of T790M mutation. We examined whether related clinicopathologic or prognostic factors in patients with relapse EGFR mutant non-small cell lung cancer (NSCLC) after treatment 1st 2nd EGFR-TKIs. retrospectively reviewed the status clinical characteristics 73 advanced recurrent NSCLC who had been treated...
As the development of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has become an issue concern, identification mechanisms responsible urgent priority. However, for research purposes, it is not easy obtain tumor samples from patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) that relapsed after treatment EGFR-TKIs. Here, using digital PCR assay as alternative and noninvasive method, we examined plasma NSCLC establish...
Olaparib (AZD2281) is an orally active Poly(ADP-ribose) polymerase (PARP) inhibitor with favorable antitumor activity in advanced ovarian and breast cancers BRCA1/2 mutations Western (USA European) studies. This Phase I dose-finding study evaluated the tolerability, pharmacokinetics, PARP inhibitory activity, of olaparib Japanese patients solid tumors. was administered as a single-dose on day 1, followed by twice-daily dosing for 28 days from 48 h after single dose. Doses were escalated 100...
Although the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for EGFR gene mutation-positive non-small cell lung cancer is well established, optimal dosing remains to be especially in elderly or frail patients.To investigate and safety low-dose erlotinib patients with cancer.Single-arm phase 2 trial Southwest Oncology Group (SWOG) 2-stage design that enrolled from 21 Japanese institutions after meeting inclusion criteria. Chemotherapy-naive EGFR-activating who were...
Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases is potentially curable by radical treatment. This study aimed to evaluate the efficacy and safety of chemoradiotherapy (CRT) for thoracic disease, including primary lesion lymph node metastases, combined local consolidative therapy (LCT) oligometastases. was a multicenter Phase II trial patients NSCLC whom CRT disease feasible. The treatment procedures included containing platinum-doublet LCT within 8 weeks starting or...
Idiopathic interstitial pneumonia (IIP) is considered to be one of the risk factors for lung cancer (LC). However, therapeutic options patients with LC complicated by IIP are not well established. In this study, we investigated feasibility and efficacy chemotherapy non-small cell (NSCLC) (NSCLC-IIP). We retrospectively analyzed 22 NSCLC-IIP who received chemotherapy. To determine how affected clinical outcomes in NSCLC, they were compared 276 NSCLC without IIP, treated alone. The response...
Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD-1), has been shown to improve overall survival (OS) in patients with previously treated advanced non-small-cell lung cancer (NSCLC) ligand (PD-L1) tumor proportion score (TPS) ≥1%. We report safety and efficacy results from the phase 1b KEYNOTE-025 study, which evaluated pembrolizumab Japanese NSCLC. Eligible had histologically/cytologically confirmed NSCLC PD-L1 TPS ≥1% received ≥1 platinum-doublet chemotherapy....
BackgroundSome patients with advanced or recurrent, epidermal growth factor receptor (EGFR) mutation-positive (EGFR M+) non-small-cell lung cancer (NSCLC) continue to receive EGFR tyrosine kinase inhibitors (TKIs) beyond radiological progression.MethodsWe analysed a cohort of 577 M+ NSCLC, who had received first-line EGFR-TKI. We classified according clinical course and treatment patterns at Response Evaluation Criteria in Solid Tumors (RECIST) progressive disease (PD). evaluated the period...
Although programmed death (PD)-1 immune checkpoint therapies target the system, relationship between inflammatory factors and clinical outcome of anti-PD-1 therapy for nonsmall cell lung cancer (NSCLC) is not fully understood. Here we examined association soluble mediators treatment with PD-1 inhibitors in patients advanced/recurrent NSCLC. In two independent cohorts, assessed levels 88 different peripheral blood before after treatment, evaluated their associations outcomes. training cohort,...
This open-label, multicenter, phase 1b/2 study assessed necitumumab plus gemcitabine and cisplatin (GC + N) in patients with previously untreated squamous non-small cell lung cancer Japan.The 1b part determined the dose for 2 part, which were randomized 1:1 to GC N or (GC) (gemcitabine 1250 mg/m2 on days 1 8; 75 day of maximum four 3-week cycles; nectimumab 800 mg 8 a cycle continued until progressive disease unacceptable toxicity). The primary endpoint was overall survival.In 181 received...
Vorinostat (suberoylanilide hydroxamic acid), a potent, oral histone deacetylase inhibitor, has demonstrated clinical activity in non-Japanese patients with various hematological and solid tumors. We sought to determine the maximum tolerated dose recommended phase II for 18 Japanese tumors (median age, 58 years; range, 25-72 years) who failed standard therapy. Patients received vorinostat 14 days followed by 7-day rest. The initial was 100 mg twice daily escalating daily. Once-daily dosing...
Purpose This phase III, randomized, placebo-controlled, double-blind study determined whether motesanib improved progression-free survival (PFS) compared with placebo in combination paclitaxel and carboplatin (P/C) East Asian patients stage IV/recurrent nonsquamous non-small-cell lung cancer. Patients Methods were randomly assigned (1:1) to receive oral 125 mg or once daily plus 200 mg/m2 IV area under the concentration-time curve 6 mg/mL ⋅ min for up six 3-week cycles. Random assignment was...
Objective: In order to examine if Tannerella forsythia stimulates the growth of Porphyromonas gingivalis , an in vitro study was performed. Background: P. and T. are often isolated simultaneously from active periodontitis sites, indicating that these bacteria somewhat interact periodontal environment. We reported previously mixed infection synergistically induced lesion formation a murine abscess model, gingipains played important role this synergism . One possible mechanisms is promotion by...